A Randomized, Open-label Study of the Effect of First Line Treatment With Tarceva in Sequential Combination With Gemcitabine, Compared to Gemcitabine Monotherapy, on Progression-free Survival in Elderly or ECOG PS of 2 Patients With Advanced Non-small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2015
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Roche
- 07 Jun 2017 Biomarkers information updated
- 01 Apr 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 19 Jun 2012 Actual patient number is 53 according to ClinicalTrials.gov.